---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-015224"
form_type: "8-K"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2025-02-19T23:59:59+00:00"
generated_at: "2026-05-26T10:26:58.864534+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics grants 50,000 CEO options and 30,000 options each to three non-employee directors

## Summary
- CEO Juan Vera awarded 50,000 stock options vesting annually over three years under 2020 Plan.
- Non-employee directors David Eansor, Katherine Knobil, and Steven Elms each receive 30,000 options with same vesting.
- Awards approved by Compensation Committee and Board on February 12, 2024.

## SEC filing metadata
- accession: 0001104659-25-015224
- form_type: 8-K
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2025-02-19T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465925015224/0001104659-25-015224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465925015224/tm257101d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-015224
- JSON: https://secwatch.observer/filing/0001104659-25-015224.json
- Plain text: https://secwatch.observer/filing/0001104659-25-015224.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.